Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People under 25 years of age, of any gender or race
• People diagnosed with one of the following blood cancers, at the stage listed:
  • Acute myeloid leukemia (primary or secondary), with very low or undetectable levels of disease on sensitive testing (MRD negative, meaning ≤0.1% on flow testing)
  • Myelodysplasia (a bone marrow disorder)
  • Acute lymphoblastic leukemia, with undetectable levels of disease on sensitive testing (MRD negative)
  • Chronic myelogenous leukemia, in chronic phase, accelerated phase, or blast crisis that has returned to a second chronic phase
  • Mixed lineage or biphenotypic acute leukemia, with undetectable levels of disease on sensitive testing (MRD negative)
  • Lymphoblastic lymphoma, currently in remission
  • Burkitt's lymphoma or leukemia, currently in remission
  • Lymphoma that has come back and is now in remission
  • Other serious blood cancers in remission, subject to approval by the principal investigator
• People who are well enough to carry out daily activities — measured by a standard health score of at least 60% (the trial team will assess this)
• People whose heart, lungs, liver, kidneys, and other organs are functioning well enough, as assessed by the trial centre
• People with no active, untreated infections — those with a possible fungal infection must have completed at least two weeks of appropriate antifungal treatment and have no current symptoms
• People aged 18 or older who are able to give their own consent, or younger patients whose parent or guardian signs the consent form
• People capable of becoming pregnant must have a negative pregnancy test before joining
• People who are sexually active and capable of becoming pregnant must agree to use an effective form of contraception (such as a diaphragm, birth control pills, injections, an IUD, surgical sterilisation, implants, or abstinence) for the full duration of treatment — sexually active men must agree to use a barrier method (such as a condom) for the full duration of treatment

Regarding the stem cell donor:

• An unrelated donor must meet the National Marrow Donor Program's criteria for donation
• An unrelated donor must match at least 9 out of 10 tissue type markers (HLA A, B, C, DRB1, and DQB1) with the patient
• A related donor with a half-match (called haploidentical) — such as a parent or other relative — must match at least 5 out of 10 tissue type markers, though donors with more matches are preferred
• The donor must be willing to receive growth factor injections (G-CSF) and undergo a stem cell collection procedure (apheresis), as only stem cells collected from the blood (not bone marrow) will be used in this trial
• The donor must pass infectious disease testing and screening as required by the trial centre

Who may not be able to join:

• People who do not meet the disease, organ function, or infection requirements listed above
• People for whom no suitable donor can be found
• People who are pregnant or breastfeeding, as several medications used in this trial may be harmful to unborn children or infants
• People currently receiving other chemotherapy, radiation therapy, immunotherapy, or any other cancer treatment not specified in this trial's protocol (post-transplant maintenance therapy may be considered after discussion with the principal investigator)
• People currently participating in another Phase 1 or Phase 2 clinical trial that involves treatment of their disease
• People with a currently active cancer other than the eligible conditions listed above — people with a previous cancer diagnosis may still be considered, provided at least one year has passed since completing treatment for that earlier cancer

Important: Always verify eligibility with the trial site directly before applying.